Background: The composite histological endpoint comprising nonalcoholic steato-
| INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD), the liver manifestation of the metabolic syndrome (MetS), encompasses a wide spectrum of liver lesions. 1 While isolated steatosis is generally considered benign, nonalcoholic steatohepatitis (NASH) represents the aggressive form of the disease responsible for accelerated liver fibrosis progression, higher rates of cirrhosis and its associated complications, and higher rates of hepatocellular carcinoma. 2 Now that the burden of NAFLD among the general population has reached 25%, 3 NASH is expected to become the leading indication for liver transplantation in the United States within 10-20 years. 4 Knowledge of the pathophysiological mechanisms driving NAFLD has advanced considerably and resultantly research in drug development has become a highly active field within which numerous therapeutic trials are underway. 5 A recent workshop conducted by the American Association for the Study of Liver Diseases concluded that therapeutic trials in NAFLD should enrol patients having an active disease defined by the presence of steatohepatitis and a NAFLD activity score (NAS) ≥ 4. 6 The first phase III trials in NASH were recently launched with the aim of demonstrating the clinical benefits of obeticholic acid (REGENERATE study, NCT02548351) and Elafibranor (RESOLVE-IT study, NCT02704403). These two trials are using clinical outcomes as study endpoints and, to be included, patients must have biopsy-proven NASH, a NAS ≥ 4 and significant/advanced F2-3 fibrosis. This enrichment of the study populations with fibrotic patients is intended to ensure that the number of required clinical events will occur during patient follow-up and within a reasonable time frame.
Because it is a condition required for inclusion in phase III trials, the composite criterion of "NASH and NAS ≥4 and fibrosis F ≥ 2" is therefore becoming an important new diagnostic target in NAFLD. More importantly, it will become an indication for treatment in clinical practice when and if these drugs receive their market authorisations. This second aspect particularly reinforces the interest of non-invasive tests able to accurately diagnose this composite histological endpoint. Several blood fibrosis tests are available but they have been usually developed for the diagnosis of advanced fibrosis and they are less accurate for earlier stages of fibrosis. 7 Serum level of apoptotic caspase-3 generated cytokeratin-18 fragments (CK18) has been shown as a candidate biomarker for NASH 8 but a large study has recently challenged its diagnostic accuracy. 9 In the present work, we aimed to evaluate the accuracy of blood fibrosis tests and CK18 for the diagnosis of "NASH and NAS ≥4 and fibrosis F ≥ 2" in a large multicentre series of NAFLD patients, and to improve the accuracy by developing an accurate blood test specifically designed for this new diagnostic target of interest.
| PATIENTS AND METHODS

| Patients
The study population was obtained by pooling the data from three published studies performed in Angers (France), 7 Antwerp (Belgium) 10 and Nice (France). 11 Inclusion criteria were biopsy-proven NAFLD as defined by the presence of liver steatosis after exclusion of concomi- 
| Histology
Liver biopsy was performed percutaneously (16-gauge Menghini in Angers and Antwerp) or during surgery (14-gauge Tru-Cut in Antwerp or hepatic wedges in Nice). In each centre, pathological examination of liver biopsies was performed by a senior expert specialised in hepatology and blinded for patient data. Steatosis, lobular inflammation and ballooning were semi-quantitatively graded using the NASH-CRN scoring system. 13 The NAS, ranging from 0 to 8, corresponded to the sum of the scores for steatosis, lobular inflammation and ballooning. 14 NASH was defined according to the latest recommendations 6, 15 as the presence of a score ≥1 for each of the three components of the NAS. "Active NASH" was defined as the presence of NASH with a NAS score ≥4. Liver fibrosis was staged from F0 to F4 according to the NASH-CRN scoring system. 13 Significant fibrosis was defined as F ≥ 2 and advanced fibrosis as F ≥ 3. Finally, the presence of an active NASH with significant fibrosis, ie NASH and NAS≥4 and fibrosis F ≥ 2, was termed "fibrotic NASH". This latter was the primary diagnostic target of the study.
A subgroup of 30 patients covering the histological spectrum of NAFLD lesions was selected in the Angers population to study the inter-centre agreement on histopathological evaluation of liver lesions. Liver biopsies were digitised using an Aperio digital slide scanner (Scanscope CS System, Aperio Technologies, Vista CA 92081, USA) image processor that provided high quality 30 000 9 30 000 pixel images at a resolution of 0.5 lm/pixel (magnification 920). Two slides were digitised for each patient: one stained with haematoxylin and eosin and one with picrosirius red.
The digitised slides were sent to the expert pathologist from each of the three investigating centres (SM, SP, AD) to score steatosis, lobular inflammation, ballooning and fibrosis according to the NASH-CRN scoring system.
| Blood parameters
All blood samples from the three original studies were taken in fasting conditions. 7, 10, 11 The blood results available from these works enabled the calculation of the following blood fibrosis tests according to published formulas: BARD, 16 FIB4, 17 and NAFLD fibrosis score (NFS). 18 Serum level of insulin were measured on fresh samples using Chimiluminescence I2000 (Abbott) in Angers, Cobas Instrument (Roche) in Antwerp, and Centaur XP (Siemens) in Nice.
HOMA was calculated as follow: fasting glucose (mmol/L) * fasting insulin (lU/mL)/22.5. To limit the influence of supra-physiological results of insulinemia induced by insulin therapy, the HOMA was capped at 10. Serum levels of CK18 were measured on frozen (À80°C) samples in each centre using the M30-Apoptosense enzyme-linked immunosorbent assay kit (PEVIVA, Bromma, Sweden).
| Statistics
Quantitative variables were expressed as mean AE standard deviation. Inter-observer agreement of the histological scoring was determined using the Fleiss' Kappa score. 19 Correlations between quantitative variables were determined using the Spearman correlation coefficient (Rs). The accuracy of non-invasive tests was evaluated using the area under the receiver operating characteristics (AUROC) and compared between tests using the Delong test.
| Development of the new blood test for the diagnosis of fibrotic NASH
To facilitate future automatic calculation by laboratory systems, only biological parameters were considered for the development of the new blood test dedicated to the diagnosis of fibrotic NASH. Variables with skewed distribution were ln transformed. The study population was randomly divided into derivation and validation sets. In the derivation set, the statistically significant variables identified by the univariate analysis (P < 0.05) were introduced in a multivariate analysis (stepwise forward binary logistic regression) whose regression formula was used to develop the new blood test. The diagnostic accuracy of the new test was then evaluated in the validation set.
| Sample size calculation
With a risk: 5%, b risk: 10%, fibrotic NASH prevalence: 25%, expected AUROC for fibrotic NASH: 0.70 for the best blood fibrosis test and 0.85 for the new test, AUROC correlation: 0.30 and bilateral testing, the required sample size for the validation set was 264
patients. The whole study population (n = 846) was therefore 2:1 randomly divided so that the validation set included 282 patients.
Statistical analyses were performed using SPSS version 18.0 software (IBM, Armonk, NY, USA) and SAS 9.1 (SAS Institute Inc., Cary, NC, USA). All authors had access to the study data and reviewed and approved the final manuscript.
3 | RESULTS
| Patient characteristics
The characteristics of the 846 patients included in the study are detailed in Table 1 
| Inter-observer agreement on histopathological evaluation of liver lesions
The liver biopsies of the 30 patients were all read by the expert pathologist from each investigating centre, for a total of 90 observations. The distribution of the recorded scores is shown in Table S1 . (Table S2 ).
| Accuracy of blood fibrosis tests and CK18 for the diagnosis of fibrotic NASH
As expected, blood fibrosis tests performed better in diagnosing advanced fibrosis and cirrhosis (Table 2 Figure S1A ) and had poor positive predictive value (FIB4: 55.3%, NFS: 38.0%; Figure S1B ).
Taken together, these results suggest that BARD, FIB4, and NFS do not perform optimally for the detection of fibrotic NASH in NAFLD patients.
CK18 correlated significantly with steatosis, lobular inflammation, ballooning and fibrosis with significant differences between most of the adjacent grades/stages (Table S3) . Furthermore, CK18 was significantly higher in patients with NASH compared to those without
(respectively: 319 AE 316 vs 217 AE 142 IU/l, P < 0.001). Despite this, CK18 showed low accuracy for the diagnosis of NASH, with an AUROC at 0.595 AE 0.019 (Table 2) . Thereafter, CK18 was evaluated as a function of NASH, NAS ≥ 4 and F ≥ 2. In the NAS < 4 and NAS ≥ 4 subgroups, CK18 levels did not differ significantly between patients with or without NASH ( Figure S2A ). Interestingly, in the four subgroups defined by NASH and NAS ≥ 4, CK18 levels were significantly higher in F ≥ 2 patients compared to F0-1 patients (Figure S2B) . Consequently, CK18 performed better in diagnosing fibrotic NASH (Table 2 ) and appeared to be a candidate biomarker for this diagnostic target.
| New blood test for the non-invasive diagnosis of fibrotic NASH
The 846 patients were 2:1 randomly divided into derivation and validation sets, between which patients characteristics were not significantly different (Table S4 ). To facilitate a future automatic calculation of the new test by laboratory systems, only biological parameters were tested in the derivation set. Multivariate analysis identified AST, HOMA and CK18 as independent predictors of fibrotic NASH (Table S5) . A new blood test combining these three parameters was derived using the regression formula of the multivariate analysis. This new test, called MACK-3 (hoMa, Ast, CK18), provides a result ranging from 0 to 1. In the derivation set, the MACK-3 thresholds corresponding to 90% sensitivity and 95% specificity for fibrotic NASH were, respectively, 0.134 and 0.550.
In the validation set, MACK-3 had a significantly higher AUROC for the diagnosis of fibrotic NASH (0.847 AE 0.030) than BARD, NFS and FIB4 (P ≤ 0.002, showed an excellent diagnostic accuracy for fibrotic NASH with 93.3% well-classified patients (Table 4) .
| Sensitivity analysis
The accuracy of MACK-3 for the diagnosis of fibrotic NASH was different across the three centres (Table S6) , likely reflecting the different populations they included. To evaluate whether there was a centre effect or this was due to the different characteristics of the three populations, we tested the influence of centre, age, sex, BMI, MetS, oral antidiabetic treatment, insulin treatment, biopsy length ≥20 mm, NAFLD/bariatric patients and derivation/ validation set. By multivariate analysis including all these parameters, only MetS was independently associated with the rate of well-classified patients by MACK-3 (Table S7 ). Diagnostic accuracy of MACK-3 as a function of MetS presence/absence is presented in Table S6 . This very low prevalence was also consistent across the three centres: 0.0% in Angers, 1.3% in Antwerp and 1.0% in Nice (P = 0.876).
Therefore, we derived the MACK-3 algorithm where we propose to use MACK-3 only in patients having MetS and/or AST ≥35 UI/L (Figure 2) . Accuracy of the MACK-3 algorithm was not significantly different between the derivation and the validation sets (Table S8) . In the whole population, the rates of patients included in the four subgroups of the MACK-3 algorithm were, respectively, 25.6%, 26.1%, 34.4% and 13.9%. The prevalence of fibrotic NASH in the 4
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subgroups of the MACK-3 algorithm was, respectively, 1.0%, 8.7%, 33.5% and 69.1% (Figure 3) . Among the patients included in the last subgroup (MetS and/or AST ≥35 UI/L with MACK-3 ≥ 0.550), 82.7% had fibrotic NASH or advanced F3-4 fibrosis (Figure 3 (Table S8 ).
| DISCUSSION
NAFLD is closely linked to obesity and insulin resistance, and consequently its treatment is primarily based on lifestyle modifications. 1 Weight loss of ≥10% is associated with a 90% resolution in NASH but less than 10% of patients are able to achieve and maintain that objective. 21 In this context, the development of new drugs to reduce liver inflammation and stop fibrosis progression in NAFLD is receiving a great amount of attention. [22] [23] [24] [25] [26] Fibrotic NASH is now used in the stratification of NAFLD severity by the latest international EASL-EASD-EASO Clinical Practice Guidelines. Interestingly, however, CK18 was significantly correlated with each of the individual liver lesions observed in NAFLD (Table S3) and was highest in patients with fibrotic NASH ( Figure S2B ). Finally, rather than a biomarker for the single diagnosis of NASH, CK18 was more globally associated with the severity of NAFLD and showed promise as a potential candidate for the non-invasive diagnosis of fibrotic NASH.
To improve the non-invasive diagnosis of fibrotic NASH, we identified relevant biomarkers by multivariate analysis in the deriva- 
V a l i d a t i o n D e r i v a t i o n V a l i d a t i o n D e r i v a t i o n V a l i d a t i o n
Fibrotic NASH (NASH and NAS≥4 and F≥2 )
Active NASH (NASH and NAS ≥4) with no/mild fibrosis (F0-1)
No Active NASH (no NASH or NAS <4) and no advanced fibrosis (F0-2) 27 In the derivation set, we found that the absence of The reading of liver biopsies by local pathologists as the different assays used to measure insulinemia could have introduced inter-centre variability in our work. 13, 28 To test this, we performed a multivariate analysis including the "center" variable and the parameters that differed significantly between the three populations. The only parameter associated with the rate of correctly classified patients by MACK-3 was the metabolic syndrome, with no effect of the "center." This suggested that the difference in correctly classified patients we observed between the three investigating sites was linked to the different prevalence of the metabolic syndrome and not to local expertise or procedures. The reproducibility study between the three pathologists involved in the study showed an inter-observer agreement that was very close to what has been previously observed between nine expert pathologists of the NASH-CRN. 13 These results validate the expertise of our pathologists and therefore the quality of the liver biopsy examinations performed in our work. Nonetheless, we acknowledge that further studies are required to independently validate the diagnostic accuracy of MACK-3 in larger, "real-life"
NAFLD patient sets, and to evaluate inter-laboratory reproducibility. Despite it is well established that fibrosis stage is the main predictor of NAFLD prognosis, 30 it remains to demonstrate that fibrotic NASH is predictive of patient outcome. Liver biopsy is an imperfect reference for liver lesions because of sample bias and suboptimal inter-observer reproducibility. 31, 32 This is well illustrated by our results: despite our three pathologists involved were all senior experts specialised in hepatology, inter-observer reproducibility for fibrotic NASH was modest with kappa index at 0.60.
Due to this lack of gold standard, it is not possible to assess the true diagnostic accuracy of MACK-3. Longitudinal studies circumvent this limitation by evaluating the prognostic significance of non-invasive tests. 33 Such longitudinal works are now required to validate if a blood test targeted for fibrotic NASH, like MACK-3, accurately identifies the NAFLD patients who have impaired prognosis and therefore require treatment with the upcoming new drugs.
In conclusion, MACK-3 is a new blood test combining AST, HOMA and CK18 for an accurate diagnosis of fibrotic NASH. This test will improve the screening of patients for therapeutic trials in NASH and, in the future, the identification of patients who will benefit from treatment with the new drugs currently under evaluation. 
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